{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:18:09Z","timestamp":1788459489659,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019084","name":"Kobe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019084","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11102-026-01735-0","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:50:04Z","timestamp":1784879404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors"],"prefix":"10.1007","volume":"29","author":[{"given":"Yasutaka","family":"Tsujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico Gaia Costa","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Oi-Yo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Urai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genzo","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kanzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Aoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-653X","authenticated-orcid":false,"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"1735_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST et al (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1735_CR2","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU et al (2021) A pituitary society update to acromegaly management guidelines. Pituitary 24:1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"key":"1735_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaf020","author":"MR Gadelha","year":"2025","unstructured":"Gadelha MR, Wildemberg LE, Marques NV, Kasuki L (2025) Medical treatment of acromegaly: navigating the present, shaping the future. Endocr Rev. https:\/\/doi.org\/10.1210\/endrev\/bnaf020","journal-title":"Endocr Rev"},{"key":"1735_CR5","doi-asserted-by":"publisher","first-page":"101422","DOI":"10.1016\/j.ghir.2021.101422","volume":"60\u201361","author":"S Siegel","year":"2021","unstructured":"Siegel S, Kirstein CF, Schr\u00f6der B et al (2021) Illness-related burden, personal resources and need for support in patients with acromegaly: Results of a focus group analysis. Growth Horm IGF Res 60\u201361:101422. https:\/\/doi.org\/10.1016\/j.ghir.2021.101422","journal-title":"Growth Horm IGF Res"},{"key":"1735_CR6","doi-asserted-by":"publisher","first-page":"101389","DOI":"10.1016\/j.ghir.2021.101389","volume":"59","author":"MD Whittington","year":"2021","unstructured":"Whittington MD, Munoz KA, Whalen JD et al (2021) Economic and clinical burden of comorbidities among patients with acromegaly. Growth Horm IGF Res 59:101389. https:\/\/doi.org\/10.1016\/j.ghir.2021.101389","journal-title":"Growth Horm IGF Res"},{"key":"1735_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s11102-018-0908-0","volume":"21","author":"LP Leonart","year":"2018","unstructured":"Leonart LP, Borba HHL, Ferreira VL et al (2018) Cost-effectiveness of acromegaly treatments: a systematic review. Pituitary 21:642\u2013652. https:\/\/doi.org\/10.1007\/s11102-018-0908-0","journal-title":"Pituitary"},{"key":"1735_CR8","doi-asserted-by":"publisher","first-page":"1573721","DOI":"10.3389\/fendo.2025.1573721","volume":"16","author":"E Venegas Moreno","year":"2025","unstructured":"Venegas Moreno E, Jim\u00e9nez-S\u00e1nchez A, Rem\u00f3n-Ruiz P et al (2025) Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study. Front Endocrinol (Lausanne) 16:1573721. https:\/\/doi.org\/10.3389\/fendo.2025.1573721","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1735_CR9","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.arcmed.2023.102924","volume":"54","author":"M Marques-Pamies","year":"2023","unstructured":"Marques-Pamies M, Gil J, Jord\u00e0 M, Puig-Domingo M (2023) Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly. Arch Med Res 54:102924. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102924","journal-title":"Arch Med Res"},{"key":"1735_CR10","doi-asserted-by":"publisher","first-page":"648411","DOI":"10.3389\/fendo.2021.648411","volume":"12","author":"M Puig-Domingo","year":"2021","unstructured":"Puig-Domingo M, Bernab\u00e9u I, Pic\u00f3 A et al (2021) Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne) 12:648411. https:\/\/doi.org\/10.3389\/fendo.2021.648411","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1735_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.12731","volume":"83","author":"M Puig Domingo","year":"2015","unstructured":"Puig Domingo M (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol (Oxf) 83:3\u201314. https:\/\/doi.org\/10.1111\/cen.12731","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1735_CR12","doi-asserted-by":"publisher","first-page":"107423","DOI":"10.18632\/oncotarget.22475","volume":"8","author":"N Jacobi","year":"2017","unstructured":"Jacobi N, Seeboeck R, Hofmann E et al (2017) Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget 8:107423\u2013107440. https:\/\/doi.org\/10.18632\/oncotarget.22475","journal-title":"Oncotarget"},{"key":"1735_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41467-017-00451-5","volume":"8","author":"S Chia","year":"2017","unstructured":"Chia S, Low J-L, Zhang X et al (2017) Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun 8:435. https:\/\/doi.org\/10.1038\/s41467-017-00451-5","journal-title":"Nat Commun"},{"key":"1735_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A et al (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359:920\u2013926. https:\/\/doi.org\/10.1126\/science.aao2774","journal-title":"Science"},{"key":"1735_CR15","doi-asserted-by":"publisher","first-page":"19103","DOI":"10.1038\/srep19103","volume":"6","author":"M Zanoni","year":"2016","unstructured":"Zanoni M, Piccinini F, Arienti C et al (2016) 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep 6:19103. https:\/\/doi.org\/10.1038\/srep19103","journal-title":"Sci Rep"},{"key":"1735_CR16","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis E, Kretzschmar K, Clevers H (2020) Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc 15:3380\u20133409. https:\/\/doi.org\/10.1038\/s41596-020-0379-4","journal-title":"Nat Protoc"},{"key":"1735_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1233714","author":"E Laporte","year":"2023","unstructured":"Laporte E, Vankelecom H (2023) Organoid models of the pituitary gland in health and disease. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2023.1233714","journal-title":"Front Endocrinol"},{"key":"1735_CR18","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.stemcr.2023.05.002","volume":"18","author":"S Taga","year":"2023","unstructured":"Taga S, Suga H, Nakano T et al (2023) Generation and purification of ACTH-secreting hPSC-derived pituitary cells for effective transplantation. Stem Cell Rep 18:1657\u20131671. https:\/\/doi.org\/10.1016\/j.stemcr.2023.05.002","journal-title":"Stem Cell Rep"},{"key":"1735_CR19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae228","author":"R Cui","year":"2024","unstructured":"Cui R, Duan H, Hu W et al (2024) Establishment of human pituitary neuroendocrine tumor derived organoid and its pilot application for drug screening. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae228","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12935-023-02863-4","volume":"23","author":"R Saksis","year":"2023","unstructured":"Saksis R, Rogoza O, Niedra H et al (2023) Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues. Cancer Cell Int 23:25. https:\/\/doi.org\/10.1186\/s12935-023-02863-4","journal-title":"Cancer Cell Int"},{"key":"1735_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s11102-021-01192-x","volume":"25","author":"A Ishida","year":"2022","unstructured":"Ishida A, Shichi H, Fukuoka H et al (2022) Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay. Pituitary 25:238\u2013245. https:\/\/doi.org\/10.1007\/s11102-021-01192-x","journal-title":"Pituitary"},{"key":"1735_CR22","doi-asserted-by":"publisher","first-page":"916982","DOI":"10.3389\/fonc.2022.916982","volume":"12","author":"A Ishida","year":"2022","unstructured":"Ishida A, Shichi H, Fukuoka H et al (2022) Temozolomide and capecitabine treatment for an aggressive somatotroph pituitary tumor: a case report and literature review. Front Oncol 12:916982. https:\/\/doi.org\/10.3389\/fonc.2022.916982","journal-title":"Front Oncol"},{"key":"1735_CR23","doi-asserted-by":"publisher","first-page":"bvab055","DOI":"10.1210\/jendso\/bvab055","volume":"5","author":"Y Tsujimoto","year":"2021","unstructured":"Tsujimoto Y, Shichi H, Fukuoka H et al (2021) Tumor shrinkage by metyrapone in cushing disease exhibiting glucocorticoid-induced positive feedback. J Endocr Soc 5:bvab055. https:\/\/doi.org\/10.1210\/jendso\/bvab055","journal-title":"J Endocr Soc"},{"key":"1735_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12022-023-09768-y","volume":"34","author":"S Ezzat","year":"2023","unstructured":"Ezzat S, de Herder WW, Volante M, Grossman A (2023) The driver role of pathologists in endocrine oncology: what clinicians seek in pathology reports. Endocr Pathol 34:437\u2013454. https:\/\/doi.org\/10.1007\/s12022-023-09768-y","journal-title":"Endocr Pathol"},{"key":"1735_CR25","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5","journal-title":"Sci Rep"},{"key":"1735_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1365-2265.2004.02191.x","volume":"62","author":"N Karavitaki","year":"2005","unstructured":"Karavitaki N, Botusan I, Radian S et al (2005) The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 62:282\u2013288. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02191.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1735_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1530\/acta.0.1060175","volume":"106","author":"JWR Nortier","year":"1984","unstructured":"Nortier JWR, Croughs RJM, Donker GH et al (1984) Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests. Eur J Endocrinol 106:175\u2013183. https:\/\/doi.org\/10.1530\/acta.0.1060175","journal-title":"Eur J Endocrinol"},{"key":"1735_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1507\/endocrj.ej11-0177","volume":"59","author":"M Kato","year":"2012","unstructured":"Kato M, Inoshita N, Sugiyama T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59:221\u2013228. https:\/\/doi.org\/10.1507\/endocrj.ej11-0177","journal-title":"Endocr J"},{"key":"1735_CR29","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/jc.2003-031344","volume":"89","author":"LJ Hofland","year":"2004","unstructured":"Hofland LJ, van der Hoek J, van Koetsveld PM et al (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577\u20131585. https:\/\/doi.org\/10.1210\/jc.2003-031344","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR30","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1210\/jc.2017-00135","volume":"102","author":"F Gatto","year":"2017","unstructured":"Gatto F, Feelders RA, Franck SE et al (2017) In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas. J Clin Endocrinol Metab 102:2009\u20132018. https:\/\/doi.org\/10.1210\/jc.2017-00135","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR31","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1210\/clinem\/dgac675","volume":"108","author":"F Gatto","year":"2023","unstructured":"Gatto F, Feelders RA, van Koetsveld PM et al (2023) Dissecting the in vitro efficacy of octreotide and cabergoline in GH- and GH\/PRL-secreting pituitary tumors. J Clin Endocrinol Metab 108:e98\u2013e109. https:\/\/doi.org\/10.1210\/clinem\/dgac675","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00701-018-3575-z","volume":"160","author":"BM Dijkstra","year":"2018","unstructured":"Dijkstra BM, Motekallemi A, den Dunnen WFA et al (2018) SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery. Acta Neurochir (Wien) 160:1539\u20131546. https:\/\/doi.org\/10.1007\/s00701-018-3575-z","journal-title":"Acta Neurochir (Wien)"},{"key":"1735_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.humpath.2017.11.008","volume":"72","author":"A Kasajima","year":"2018","unstructured":"Kasajima A, Papotti M, Ito W et al (2018) High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Hum Pathol 72:144\u2013152. https:\/\/doi.org\/10.1016\/j.humpath.2017.11.008","journal-title":"Hum Pathol"},{"key":"1735_CR34","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"Volante M, Brizzi MP, Faggiano A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172\u20131182. https:\/\/doi.org\/10.1038\/modpathol.3800954","journal-title":"Mod Pathol"},{"key":"1735_CR35","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3390\/jcm8111962","volume":"8","author":"A Akirov","year":"2019","unstructured":"Akirov A, Asa SL, Amer L et al (2019) The clinicopathological spectrum of acromegaly. J Clin Med 8:1962. https:\/\/doi.org\/10.3390\/jcm8111962","journal-title":"J Clin Med"},{"key":"1735_CR36","doi-asserted-by":"publisher","first-page":"vdab065","DOI":"10.1093\/noajnl\/vdab065","volume":"3","author":"S Shuford","year":"2021","unstructured":"Shuford S, Lipinski L, Abad A et al (2021) Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neuro-Oncol Adv 3:vdab065. https:\/\/doi.org\/10.1093\/noajnl\/vdab065","journal-title":"Neuro-Oncol Adv"},{"key":"1735_CR37","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.3390\/ijms22094322","volume":"22","author":"S Lenin","year":"2021","unstructured":"Lenin S, Ponthier E, Scheer KG et al (2021) A drug screening pipeline using 2D and 3D patient-derived in vitro models for pre-clinical analysis of therapy response in glioblastoma. Int J Mol Sci 22:4322. https:\/\/doi.org\/10.3390\/ijms22094322","journal-title":"Int J Mol Sci"},{"key":"1735_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2024.101893","author":"M Marazuela","year":"2024","unstructured":"Marazuela M, Mart\u00ednez-Hernandez R, Marques-Pamies M et al (2024) Predictors of biochemical response to somatostatin receptor ligands in acromegaly. Best Pract Res Clin Endocrinol Metab. https:\/\/doi.org\/10.1016\/j.beem.2024.101893","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1735_CR39","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa387","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, Korevaar TIM, van Meyel SWF et al (2020) Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa387","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11102-023-01362-z","volume":"27","author":"S Urai","year":"2024","unstructured":"Urai S, Yamamoto M, Yamamoto N et al (2024) Newer parameters of the octreotide test in patients with acromegaly. Pituitary 27:33\u201343. https:\/\/doi.org\/10.1007\/s11102-023-01362-z","journal-title":"Pituitary"},{"key":"1735_CR41","doi-asserted-by":"publisher","first-page":"1269787","DOI":"10.3389\/fendo.2023.1269787","volume":"14","author":"M Marques-Pamies","year":"2023","unstructured":"Marques-Pamies M, Gil J, Valassi E et al (2023) Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly. Front Endocrinol 14:1269787. https:\/\/doi.org\/10.3389\/fendo.2023.1269787","journal-title":"Front Endocrinol"},{"key":"1735_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","volume":"77","author":"A Heck","year":"2012","unstructured":"Heck A, Ringstad G, Fougner SL et al (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly: Intensity of somatotroph adenoma on T2-weighted MRI. Clin Endocrinol (Oxf) 77:72\u201378. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04286.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1735_CR43","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1530\/ERC-16-0356","volume":"23","author":"I Potorac","year":"2016","unstructured":"Potorac I, Petrossians P, Daly AF et al (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23:871\u2013881. https:\/\/doi.org\/10.1530\/ERC-16-0356","journal-title":"Endocr Relat Cancer"},{"key":"1735_CR44","doi-asserted-by":"publisher","first-page":"101502","DOI":"10.1016\/j.ghir.2022.101502","volume":"67","author":"ET Durmu\u015f","year":"2022","unstructured":"Durmu\u015f ET, Atmaca A, Kefeli M et al (2022) Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res 67:101502. https:\/\/doi.org\/10.1016\/j.ghir.2022.101502","journal-title":"Growth Horm IGF Res"},{"key":"1735_CR45","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","volume":"16","author":"J Brzana","year":"2013","unstructured":"Brzana J, Yedinak CG, Gultekin SH et al (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16:490\u2013498. https:\/\/doi.org\/10.1007\/s11102-012-0445-1","journal-title":"Pituitary"},{"key":"1735_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.4103\/JOC.JOC_23_18","volume":"35","author":"K Tripathy","year":"2018","unstructured":"Tripathy K, Mishra A, Singh AK et al (2018) Immunocytochemistry using liquid-based cytology: a tool in hormone receptor analysis of breast cancer. J Cytol 35:260\u2013264. https:\/\/doi.org\/10.4103\/JOC.JOC_23_18","journal-title":"J Cytol"},{"key":"1735_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00428-010-1025-2","volume":"458","author":"R Nishimura","year":"2011","unstructured":"Nishimura R, Aogi K, Yamamoto T et al (2011) Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch 458:153\u2013158. https:\/\/doi.org\/10.1007\/s00428-010-1025-2","journal-title":"Virchows Arch"},{"key":"1735_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/cyt.13030","volume":"32","author":"P Gupta","year":"2021","unstructured":"Gupta P, Gupta N, Suri V et al (2021) Cytomorphological features of cervical small cell neuroendocrine carcinoma in SurePath\u2122 liquid-based cervical samples. Cytopathology 32:813\u2013818. https:\/\/doi.org\/10.1111\/cyt.13030","journal-title":"Cytopathology"},{"key":"1735_CR49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/science.288.5463.154","volume":"288","author":"M Rocheville","year":"2000","unstructured":"Rocheville M, Lange DC, Kumar U et al (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154\u2013157. https:\/\/doi.org\/10.1126\/science.288.5463.154","journal-title":"Science"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01735-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01735-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01735-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:42:07Z","timestamp":1788457327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01735-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01735-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9461574\/v1","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures complied with the protocol approved by the Research Ethics Committee of Kobe University Hospital and Moriyama Memorial Hospital (IRB #1363 and B240223, respectively) and adhered to the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants prior to surgery and sample collection.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"131"}}